Rickard Sandin

2.4k total citations · 1 hit paper
62 papers, 1.6k citations indexed

About

Rickard Sandin is a scholar working on Pulmonary and Respiratory Medicine, Economics and Econometrics and Oncology. According to data from OpenAlex, Rickard Sandin has authored 62 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 20 papers in Economics and Econometrics and 15 papers in Oncology. Recurrent topics in Rickard Sandin's work include Prostate Cancer Treatment and Research (18 papers), Renal cell carcinoma treatment (16 papers) and Economic and Financial Impacts of Cancer (12 papers). Rickard Sandin is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Renal cell carcinoma treatment (16 papers) and Economic and Financial Impacts of Cancer (12 papers). Rickard Sandin collaborates with scholars based in Sweden, United States and United Kingdom. Rickard Sandin's co-authors include Tony Mok, J. Corral, Yi‐Long Wu, Tao Wang, Eric Sbar, Kazuhiko Nakagawa, Maria Rita Migliorino, R. Linke, Xiangdong Zhou and Ki Hyeong Lee and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Rickard Sandin

54 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

2017 854 citations Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rickard Sandin Sweden	17	1.3k	819	417	339	203	62	1.6k
Harpreet Singh United States	24	647 0.5×	1.0k 1.3×	495 1.2×	427 1.3×	119 0.6×	101	1.8k
Xun Lin United States	23	1.4k 1.1×	943 1.2×	823 2.0×	617 1.8×	96 0.5×	94	2.2k
Penelope A. Bradbury Canada	29	1.1k 0.9×	1.1k 1.3×	604 1.4×	419 1.2×	116 0.6×	112	2.0k
Patricia Cortazar United States	17	404 0.3×	872 1.1×	221 0.5×	402 1.2×	182 0.9×	37	1.5k
Haolan Lu United States	16	492 0.4×	1.2k 1.5×	384 0.9×	111 0.3×	78 0.4×	33	1.6k
Brett E. Houk United States	17	711 0.6×	606 0.7×	950 2.3×	247 0.7×	61 0.3×	49	1.6k
Jamal Tarazi United States	24	2.0k 1.5×	1.0k 1.3×	1.4k 3.4×	960 2.8×	168 0.8×	65	2.6k
Kristine Pemberton United Kingdom	13	2.0k 1.5×	1.6k 1.9×	490 1.2×	358 1.1×	29 0.1×	14	2.3k
Katarína Petráková Czechia	23	1.4k 1.1×	2.1k 2.6×	645 1.5×	989 2.9×	63 0.3×	66	2.8k
Thomas Björk Sweden	22	2.0k 1.6×	787 1.0×	446 1.1×	203 0.6×	83 0.4×	35	2.8k

Countries citing papers authored by Rickard Sandin

Since Specialization

Citations

This map shows the geographic impact of Rickard Sandin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rickard Sandin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rickard Sandin more than expected).

Fields of papers citing papers by Rickard Sandin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rickard Sandin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rickard Sandin. The network helps show where Rickard Sandin may publish in the future.

Co-authorship network of co-authors of Rickard Sandin

This figure shows the co-authorship network connecting the top 25 collaborators of Rickard Sandin. A scholar is included among the top collaborators of Rickard Sandin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rickard Sandin. Rickard Sandin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Bhavesh, Rickard Sandin, Yun Liu, et al.. (2025). Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. ClinicoEconomics and Outcomes Research. Volume 17. 289–302.

Veenstra, David L., Adam Brufsky, Timothy Pluard, et al.. (2025). First-line cyclin-dependent kinase 4 and 6 inhibitors in combination with an aromatase inhibitor for HR+/HER2- metastatic breast cancer: A real-world cost-effectiveness assessment in a US Medicare-eligible population. Journal of Managed Care & Specialty Pharmacy. 31(10). 1039–1050.

Pluard, Timothy, et al.. (2025). Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer. ClinicoEconomics and Outcomes Research. Volume 17. 247–264. 1 indexed citations

George, Daniel J., Zachary Klaassen, Rickard Sandin, et al.. (2024). Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. JAMA Network Open. 7(12). e2448707–e2448707. 1 indexed citations

George, Daniel J., Neeraj Agarwal, Krishnan Ramaswamy, et al.. (2024). Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. 27(4). 765–775. 3 indexed citations

Samjoo, Imtiaz A., Alexandra Hall, Mary Lou Smith, et al.. (2024). A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib. Journal of Comparative Effectiveness Research. 13(10). e240111–e240111. 6 indexed citations

Freedland, Stephen J., Krishnan Ramaswamy, Rickard Sandin, et al.. (2023). Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 21(4). 419–429. 2 indexed citations

Freedland, Stephen J., Rickard Sandin, Scott T. Tagawa, et al.. (2021). 609P Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. Annals of Oncology. 32. S650–S651. 7 indexed citations

Tagawa, Scott T., Krishnan Ramaswamy, Jack Mardekian, et al.. (2021). Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer and Prostatic Diseases. 24(4). 1032–1040. 40 indexed citations

10.

Tagawa, Scott T., et al.. (2020). 679P Treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study. Annals of Oncology. 31. S541–S542. 12 indexed citations

11.

Ramaswamy, Krishnan, Stanislav Lechpammer, Jack Mardekian, et al.. (2020). Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. Advances in Therapy. 37(5). 2083–2097. 13 indexed citations

12.

Beisland, Christian, T.B. Johannesen, Olbjørn Klepp, et al.. (2017). Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. OncoTargets and Therapy. Volume 10. 371–385. 27 indexed citations

13.

Wu, Yi‐Long, Ying Cheng, Xiangdong Zhou, et al.. (2017). Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 18(11). 1454–1466. 854 indexed citations breakdown →

14.

Lindskog, Magnus, Rickard Sandin, Jan Kowalski, et al.. (2017). Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology Seminars and Original Investigations. 35(9). 541.e15–541.e22. 22 indexed citations

15.

Abògúnr̀in, Ṣẹ̀yẹ, et al.. (2016). Sunitinib Dosing Schedules in The Management of Metastatic Renal Cell Carcinoma: A Meta-Analysis. Value in Health. 19(7). A711–A711.

16.

Négrier, Sylvie, Andrew G. Bushmakin, Joseph C. Cappelleri, et al.. (2014). Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. European Journal of Cancer. 50(10). 1766–1771. 16 indexed citations

17.

Harmenberg, Ulrika, Per Sandström, Sven Lundstam, et al.. (2013). Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). British Journal of Cancer. 108(7). 1541–1549. 79 indexed citations

18.

Valle, Juan W., Patricia Niccoli, Jean‐Luc Raoul, et al.. (2011). Updated Overall Survival Data From a Phase III Study of Sunitinib Vs. Placebo in Patients With Advanced, Unresectable Pancreatic Neuroendocrine Tumour (NET). European Journal of Cancer. 47. 2 indexed citations

19.

Ishak, Jack, Juan W. Valle, Eric Van Cutsem, et al.. (2011). Overall Survival (OS) Analysis of Sunitinib (SU) after Adjustment for Crossover (CO) in Patients with Pancreatic Neuroendocrine Tumors (NET). Neuroendocrinology. 94. 27–28. 1 indexed citations

20.

Benedict, Ágnes, Robert A. Figlin, Per Sandström, et al.. (2011). Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma. British Journal of Urology. 108(5). 665–672. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact